BioSim™ Nivolumab (Human) ELISA Kit

BioSim™ Nivolumab (Human) ELISA Kitis available at Gentaur for Next week Delivery.

ELISA kit for the quantitative measurement of free Nivolumab in human serum or plasma.

Description:

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumor tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumor growth in mouse tumor models. BioSim™ Nivolumab ELISA kit has been developed for specific quantification of Nivolumab concentration in human serum or plasma with high sensitivity and reproducibility. The kit is based on the sandwich principle. Standards and samples (serum or plasma) are added to the microtiter plate coated with the reactant for Nivolumab. After incubation, the wells are washed. The HRP conjugated probe is added and binds to Nivolumab captured by the reactant on the surface of the wells. Following incubation, wells are washed, and the TMB chromogen substrate is added to detect the enzymatic activity. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of Nivolumab in the sample or standard. The sample results can be determined directly using the standard curve.

Applications: This ELISA kit is used for quantitative measurement of Nivolumab in human serum and plasma

Sample Typ:e Human serum and plasma

Alternate Name: PD1, PD-1, CD279, SLEB2, hPD-1, hPD-l, hSLE1, PDCD1, CAS 946414-94-4

Features and Benefits:

Sensitivity: 0.03 μg/ml Easy, convenient, sensitive and time-saving method to measure the level of Nivolumab in human serum and plasma. Cross Reactivity: Except for Nivolumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins Detection Range: 0.03 - 1 μg/ml